World Pharma Today

  Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. Sino Biological US, Inc. proudly unveils  ProPure™ , an  industry-leading line of ultra-pure, endotoxin-free recombinant proteins ,  fully produced in the USA  at its state-of-the-art Center for Bioprocessing (C4B) facility in Houston, Texas. This new product line is specifically engineered to meet the rigorous demands of immunology research, vaccine development, animal studies, cell and gene therapy, and therapeutic protein manufacturing. The newly released proteins are manufactured using advanced purification and production technologies, ensuring endotoxin levels below the limit of quantification (LOQ). By leveraging mammalian expression systems and proprietary purification protocols, the C4B delivers high-purity proteins tailored for sensitive applications where even trace endotoxin contamination can comp...

  Accomplished industry leader to continue driving growth and product expansion across life sciences, flavors, fragrances, and specialty segments Greenfield Global Inc., a leading global producer, manufacturer, and distributor of high-purity and specialty alcohols, solvents, and custom solutions, announced today the appointment of Yvonne (Vey) Garofalo as Executive Vice President of the Specialty Chemicals and Ingredients (SC&I) business unit, which consists of the life science; food, flavor, and fragrance; personal care; and specialty business segments. Garofalo brings more than two decades of experience and a proven track record of strategic leadership and commercial excellence to Greenfield. Garofalo’s background in the life science and specialty chemical sectors, experience with both direct sales and distributor-based models, as well as her leadership in managing various global functions including Commercial, Operations, Finance, and R&D, positions her exceptionally wel...

default Pharma teams can now assess biomarker coverage across datma’s federated network with no cost, contracts, or IT support required. datma, a leader in federated real-world data access, today announced the launch of the Federated Biomarker Explorer, a new application that allows pharmaceutical teams to evaluate real-world biomarker coverage across datma’s federated network of participating data contributors before entering into a formal data partnership. This tool is designed to help teams answer a critical question early in the data sourcing process: Does this dataset contain the patient populations we need? The Federated Biomarker Explorer provides aggregate, cohort-level visibility into biomarker presence across the datma federated network. Teams can filter by a range of clinical and demographic attributes to assess feasibility. No data integration, procurement involvement, or internal IT support is required, making the application immediately accessible for teams looking to val...

  Dr. Oliver Okle is a product and service manager at Vetter The global CDMO market is projected to more than double from $161 billion in 2023 to $322.76 billion by 20331. This is only a portion of the rapid growth we’re witnessing in the broader pharmaceutical and biotech industry, driven by innovation and increased investment in research and development (R&D)2. This growth underscores the need for CDMOs to invest in advanced infrastructure, technologies, and process optimizations to stay ahead in the evolving market. In this interview, Dr. Oliver Okle, Product and Service Manager at Vetter, a globally operating CDMO, discusses the importance of trend scouting and how it helps outsourcing partners stay competitive. Dr. Okle, what are the key factors driving the rapid expansion of the pharmaceutical and biotech industries? In my experience, the primary drivers are innovation and increased R&D investment. The significant growth in the CDMO market, and the rise in R&D sp...

  Haleon today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025. This appointment follows Franck Riot deciding to leave Haleon after six years in the business. Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care. Brian McNamara, Haleon’s Chief Executive Officer commented: “I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experience of driving transformative innovation within global consumer businesses. He will be an excellent addition to our executive team as we look to build on the strong foundations we have built in recent years and unlock Haleon’s significant potential through our new Win as One strategy. “I want to take this opportunity to thank Franck for his sig...

  RHEINFELDEN, Switzerland – Life Science Newswire – Tillotts Pharma AG (“Tillotts”) proudly marks its 15th anniversary as a member of the Japanese Zeria Group, celebrating a period of exceptional growth and valuable collaboration together. The milestone was commemorated in December 2024 with Tillotts’ CEO, Thomas A. Tóth von Kiskér, and members of the leadership team visiting Zeria. During this special occasion, Mr. Sachiaki Ibe, Chairman of the Board of Directors and CEO of Zeria Pharmaceutical Co., Ltd., presented Mr. Tóth a symbolic piece of Japanese art featuring Mount Fuji as a gift to honor Zeria’s appreciation for Tillotts’ remarkable accomplishments since the acquisition. Over the past 15 years, Tillotts has consistently achieved strong double-digit growth and broadened its portfolio while leveraging the trust and support of the Zeria Group. Tillotts’ remarkable success and progress is largely due to the exceptional dedication of its employees, who constantly strive to unl...

  All4Labels Global Packaging Group , a global leader in digital and sustainable labeling solutions, has undertaken a significant expansion of its operations in South Africa. The Group has made strategic investments in infrastructure and technology to enhance its services in the region, marking a milestone in the company’s growth strategy. With the acquisition of a production  site in Durban  18 months ago, All4Labels expanded its market presence in South Africa. Since then, the Group has successfully integrated the facility into its global network, ensuring it aligns with the company’s high standards and operational policies. With this integration now being completed, the site will play a key role in advancing the company’s labeling services in the South African market. The South African region is strategically important for All4Labels as part of its broader growth objectives. The Group is committed to delivering outstanding value to its customers, currently served in th...